TrakCel a supplier of cellular orchestration solutions for the cell and gene therapy industry, is launching a software integration resulting from a collaborative, non-exclusive partnership with K?rber, a specialist for complete handling systems for pharmaceutical and medical products.

The collaboration results in a working integration between OCELLOS by TrakCel and PAS -X from K?rber. This will allow cell and gene therapy customers of both companies to effectively share data detailing manufacturing events, and milestones between the two systems such as starting checks, fill and finish and product release, whilst also providing full traceability and audit logs.

TrakCel’s OCELLOS has ensured that developers and other cell and gene therapy companies are able to receive notifications of the product entering and completing the manufacturing stage of the value chain. Combining OCELLOS and PAS-X, as well as by increasing potential changes that can be made to the manufacturing module for OCELLOS, will increase visibility of the steps within the manufacturing process itself. This aims to allow additional reaction time when issues occur and prevent risks of delays of therapies through the value chain and to patients, including capacity or scheduling issues. This combination also gives visibility of the manufacturing process to critical parts of the value chain.

“TrakCel has been collaborating with a range of key partners across the cell and gene therapy sector value and supply chains. Manufacturing cell and gene therapies has become as challenging as their development. Manual manufacturing processes, performed for high numbers of patients, by a shortage of highly skilled human operators, involves considerable risks and variability,” said Chris Came, VP of Global Alliance and Client Services, TrakCel. “As a result, the partnership between TrakCel and K?rber will provide visibility and orchestration within the manufacturing process itself. This will be vital to the ongoing success within the cell and gene therapy sector. We will be rolling this out throughout Q1 2022 and this will be a critical partnership within TrakCel’s collaborations through the supply and value chains of the cell and gene therapy sector.”

“Orchestration and tracking is vital within the cell and gene manufacturing process. However, unifying this into one single interface across the whole supply chain will be essential as therapies progress through the clinical phases to commercialization,” said Dr. Judith Koliwer, Principal Consultant Cell and Gene Therapy, K?rber. “Treating larger numbers of seriously ill patients suffering from indications with few therapeutic options requires everyone throughout the chains to be informed on progress and delays. The K?rber TrakCel partnership will provide visibility within the manufacturing of these therapies, and fit into TrakCel’s orchestration across the wider supply chain across the chain.”